Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;26(3):379-85.
doi: 10.3346/jkms.2011.26.3.379. Epub 2011 Feb 25.

Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease

Jae Seung Lee  1 , Jin Won Huh, Eun Jin Chae, Joon Beom Seo, Seung Won Ra, Ji-Hyun Lee, Eun-Kyung Kim, Young Kyung Lee, Tae-Hyung Kim, Woo Jin Kim, Jin Hwa Lee, Sang-Min Lee, Sangyeub Lee, Seong Yong Lim, Tae Rim Shin, Ho Il Yoon, Seung Soo Sheen, Yeon-Mok Oh, Sang-Do Lee
Affiliations

Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease

Jae Seung Lee et al. J Korean Med Sci. 2011 Mar.

Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and responses to therapies are highly variable. The aim of this study was to identify the predictors of pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. A total of 127 patients with stable COPD from the Korean Obstructive Lung Disease (KOLD) Cohort, which were prospectively recruited from June 2005 to September 2009, were analyzed retrospectively. The prediction models for the FEV(1), FVC and IC/TLC changes after 3 months of treatment with salmeterol/fluticasone were constructed by using multiple, stepwise, linear regression analysis. The prediction model for the FEV(1) change after 3 months of treatment included wheezing history, pre-bronchodilator FEV(1), post-bronchodilator FEV(1) change and emphysema extent on CT (R = 0.578). The prediction models for the FVC change after 3 months of treatment included pre-bronchodilator FVC, post-bronchodilator FVC change (R = 0.533), and those of IC/ TLC change after 3 months of treatment did pre-bronchodilator IC/TLC and post-bronchodilator FEV(1) change (R = 0.401). Wheezing history, pre-bronchodilator pulmonary function, bronchodilator responsiveness, and emphysema extent may be used for predicting the pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD.

Keywords: Adrenergic beta-Agonists; Corticosteroids; Emphysema; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests.

PubMed Disclaimer

Conflict of interest statement

J. S. Lee, S.W. Ra, E. J. Chae, J-H Lee, E-K Kim, Y. K. Lee, T-H Kim, J. W. Huh, W. J. Kim, J. H. Lee, S-M Lee, S. Y. Lee, S. Y. Lim, T. R. Shin, H. I. Yoon and S. S. Sheen have no conflicts of interest to disclose. J. B. Seo has been an investigator in a government-sponsored study (2006-2008 Korea Science and Engineering Foundation).

Y-M. Oh has been an investigator in university-sponsored studies (Asan Institute for Life Science, University of Ulsan College of Medicine) and an industry-sponsored study (MSD Korea, and AstraZeneca Korea), and has participated as a speaker at scientific meetings organized and financed by various pharmaceutical companies (Handok, GlaxoSmithKline, AstraZeneca Korea, MSD Korea, and Boehringer Ingelheim) and a magazine company (Korea Doctors' Weekly). S-D. Lee serves as a consultant to GlaxoSmithKline, and has participated as a speaker at scientific meetings organized and financed by various pharmaceutical companies (GlaxoSmithKline, AstraZeneca Korea, and Boehringer Ingelheim).

Figures

Fig. 1
Fig. 1
Patients selection.
See this image and copyright information in PMC

References

    1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555. - PubMed
    1. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303. - PMC - PubMed
    1. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–1909. - PubMed
    1. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084–1091. - PubMed
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed

Publication types

MeSH terms